Johnson & Johnson ordered to pay $72m in court ruling connecting talcum powder to ovarian cancer


johnson johnson fined $72 million for talcum powder links to cancer

 

 

 

 

 

 

 

 

 

26 February 2016

In a legal case brought against baby product manufacturer Johnson & Johnson by a woman who claimed that her daily use of Johnson & Johnson products caused ovarian cancer, were ordered to pay $72 million

Jacqueline Fox, from Alabama, said that she used Johnson’s talc-based Baby Powder and Shower to Shower products for more than 35 years and made the claim that the products are responsible for her ovarian cancer. Unfortunately Fox died from her condition before the ruling on her case could be given.

Johnson & Johnson has been ordered by a Missouri State jury to pay a hefty $72 million fine for damages to the family of the woman.

There has been many studies into the link between talc and cancer. Several studies link talc powder to ovarian cancer a product found in many Johnson & Johnson products. In 23 case-controlled studies conducted by the International Journal of Gynecological Cancer in May of 2015, they found that talc use increased the risk of ovarian cancer by 30-60 percent in “almost all well-designed studies.”

The International Journal of Gynecological Cancer concluded that their results “suggest that talc use causes ovarian cancer.” Several other recent studies, including one conducted by the Journal of the National Cancer Institute, confirmed those same results.

There is evidence that Johnson & Johnson was aware of the ill-effects of talc in the 1980s according to Jere Beasley, one of the lawyers representing the Fox family. “They knew as far back as the 1980s of the risk.” And yet, they did not remove it from their products.

Further Study
Johnson & Johnson knew for decades that asbestos lurked in its Baby Powder
Holistic doctors mysterious deaths, they uncovered cancer agent in vaccines
Researchers find nail polish chemical in women’s bodies
85% of tampons contain cancer causing glyphosate
In Profile : Smith & Nephew Plc
Health